To include your compound in the COVID-19 Resource Center, submit it here.

AzurRx reports Phase IIa data for MS1819 in chronic pancreatitis

In September, AzurRx BioPharma Inc. (NASDAQ:AZRX) reported data from 6 patients with chronic pancreatitis in a Phase IIa trial showing that once-daily MS1819 for 48-60

Read the full 255 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE